This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Coherus BioSciences Inc (CHRS)

NASDAQ: Health Care

Company Balance Sheet
Dec 2014 Dec 2013
Cash and Equivalents 150.39M 39.55M
Receivables 4.23M 385.00K
Inventories 0.00 0.00
Other Current Assets 3.97M 0.00
Total Current Assets 179.14M 45.68M
Property, Plant & Equipment, Gross 5.76M 2.37M
Accumulated Depreciation & Depletion 1.29M 625.00K
Property, Plant & Equipment, Net 4.47M 1.74M
Intangibles 2.62M 0.00
Other Non-Current Assets 50.00K 27.00K
Total Non-Current Assets 8.09M 1.77M
Liabilities & Shareholder Equity
Total Assets 187.22M 47.45M
Accounts Payable 13.79M 3.69M
Short Term Debt 0.00 3.09M
Other Current Liabilities 5.76M 24.27M
Total Current Liabilities 51.78M 53.70M
Long Term Debt 0.00 0.00
Deferred Income Taxes 0.00 0.00
Other Non-Current Liabilities 68.68M 36.13M
Minority Interest -44.00K 0.00
Total Non-Current Liabilities 68.64M 90.82M
Total Liabilities 120.42M 144.52M
Preferred Stock Equity 0.00 0.00
Common Stock Equity 66.80M -97.08M
Common Par 3.00K 1.00K
Additional Paid In Capital 254.05M 2.51M
Cumulative Translation Adjustment 0.00 0.00
Retained Earnings -186.72M -99.59M
Treasury Stock 0.00 0.00
Other Equity Adjustments -525.00K 0.00
Total Capitalization 66.80M -97.08M
Total Equity 66.80M -97.08M
Total Liabilities & Stock Equity 187.22M 47.45M
Total Common Shares Outstanding 33.26M 32.05M
Preferred Shares 0.00 0.00
Treasury Shares 0.00 0.00
Basic Weighted Shares Outstanding 8.19M 14.69M
Diluted Weighted Shares Outstanding 8.19M 14.69M
Number of Employees 66 NA
Number of Part-Time Employees 0 NA

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

CHRS Coherus BioSciences Inc

Chart of CHRS

Analysts Ratings for CHRS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

CHRS Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs